Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Kidney Cancer | Study Protocol

The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

Authors: Hilin Yildirim, Christiaan V Widdershoven, Maureen JB Aarts, Axel Bex, Haiko J Bloemendal, Deirdre M Bochove-Overgaauw, Paul Hamberg, Karin H Herbschleb, Tom van der Hulle, Brunolf W Lagerveld, Martijn GH van Oijen, Sjoukje F Oosting, Johannes V van Thienen, Astrid AM van der Veldt, Hans M Westgeest, Evelijn E Zeijdner, Katja KH Aben, Corina van den Hurk, Patricia J Zondervan, Adriaan D Bins

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Ongoing research in the field of both localized, locally advanced and metastatic renal cell carcinoma has resulted in the availability of multiple treatment options. Hence, many questions are still unanswered and await further research. A nationwide collaborative registry allows to collect corresponding data. For this purpose, the Dutch PROspective Renal Cell Carcinoma cohort (PRO-RCC) has been founded, for the prospective collection of long-term clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs).

Methods

PRO-RCC is designed as a multicenter cohort for all Dutch patients with renal cell carcinoma (RCC). Recruitment will start in the Netherlands in 2023. Importantly, participants may also consent to participation in a ‘Trial within cohorts’ studies (TwiCs). The TwiCs design provides a method to perform (randomized) interventional studies within the registry. The clinical data collection is embedded in the Netherlands Cancer Registry (NCR). Next to the standardly available data on RCC, additional clinical data will be collected. PROMS entail Health-Related Quality of Life (HRQoL), symptom monitoring with optional ecological momentary assessment (EMA) of pain and fatigue, and optional return to work- and/or nutrition questionnaires. PREMS entail satisfaction with care. Both PROMS and PREMS are collected through the PROFILES registry and are accessible for the patient and the treating physician.

Trial registration

Ethical board approval has been obtained (2021_218) and the study has been registered at ClinicalTrials.gov (NCT05326620).

Discussion

PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, PROMS and PREMS. By facilitating an infrastructure for the collection of prospective data on RCC, PRO-RCC will contribute to observational research in a real-world study population and prove effectiveness in daily clinical practice. The infrastructure of this cohort also enables that interventional studies can be conducted with the TwiCs design, without the disadvantages of classic RCTs such as slow patient accrual and risk of dropping out after randomization.
Literature
1.
go back to reference Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.CrossRefPubMed Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.CrossRefPubMed
3.
4.
go back to reference Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, et al. Systematic review of the role of Cytoreductive Nephrectomy in the targeted therapy era and Beyond: an Individualized Approach to metastatic renal cell carcinoma. Eur Urol. 2019;75:111–28.CrossRefPubMed Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, et al. Systematic review of the role of Cytoreductive Nephrectomy in the targeted therapy era and Beyond: an Individualized Approach to metastatic renal cell carcinoma. Eur Urol. 2019;75:111–28.CrossRefPubMed
5.
go back to reference Yang Y. Partial Versus Radical Nephrectomy in patients with renal cell carcinoma: a systematic review and Meta-analysis. Urol J. 2020;17:109–17.PubMed Yang Y. Partial Versus Radical Nephrectomy in patients with renal cell carcinoma: a systematic review and Meta-analysis. Urol J. 2020;17:109–17.PubMed
6.
go back to reference Kunath F, Schmidt S, Krabbe L-M, Miernik A, Dahm P, Cleves A, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017;5:CD012045.PubMed Kunath F, Schmidt S, Krabbe L-M, Miernik A, Dahm P, Cleves A, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017;5:CD012045.PubMed
7.
go back to reference Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, et al. Limitations of available studies prevent Reliable Comparison between Tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol. 2020;3:433–52.CrossRefPubMed Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, et al. Limitations of available studies prevent Reliable Comparison between Tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol. 2020;3:433–52.CrossRefPubMed
9.
go back to reference Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network Meta-analysis. Eur Urol Oncol. 2019;2:708–15.CrossRefPubMed Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network Meta-analysis. Eur Urol Oncol. 2019;2:708–15.CrossRefPubMed
10.
go back to reference Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66.CrossRefPubMed Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66.CrossRefPubMed
11.
go back to reference Cao G, Wu X, Wang Z, Tian X, Zhang C, Wu X, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020;10:e034626.CrossRefPubMedPubMedCentral Cao G, Wu X, Wang Z, Tian X, Zhang C, Wu X, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open. 2020;10:e034626.CrossRefPubMedPubMedCentral
12.
go back to reference Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, et al. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2021;70:265–73.CrossRefPubMed Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, et al. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2021;70:265–73.CrossRefPubMed
13.
go back to reference Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28:5197–201.CrossRefPubMedPubMedCentral Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28:5197–201.CrossRefPubMedPubMedCentral
14.
go back to reference Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute’s Cooperative Group clinical trials. J Natl Cancer Inst. 2016;108:djv324.CrossRefPubMed Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute’s Cooperative Group clinical trials. J Natl Cancer Inst. 2016;108:djv324.CrossRefPubMed
15.
go back to reference Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors Associated with Age Disparities among Cancer clinical trial participants. JAMA Oncol. 2019;5:1769–73.CrossRefPubMed Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors Associated with Age Disparities among Cancer clinical trial participants. JAMA Oncol. 2019;5:1769–73.CrossRefPubMed
16.
go back to reference Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.CrossRefPubMedPubMedCentral Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.CrossRefPubMedPubMedCentral
17.
go back to reference Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ. 2010;340:c1066.CrossRefPubMed Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ. 2010;340:c1066.CrossRefPubMed
18.
go back to reference Young-Afat DA, Gal R, Gerlich S, Burbach JPM, van der Velden JM, van den Bongard DHJG, et al. Oncology patients were found to understand and accept the trials within cohorts design. J Clin Epidemiol. 2021;130:135–42.CrossRefPubMed Young-Afat DA, Gal R, Gerlich S, Burbach JPM, van der Velden JM, van den Bongard DHJG, et al. Oncology patients were found to understand and accept the trials within cohorts design. J Clin Epidemiol. 2021;130:135–42.CrossRefPubMed
21.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
22.
go back to reference Versteegh M, Vermeulen MM, M A A Evers K, de Wit S, Prenger GA. A Stolk E. Dutch Tariff for the five-level version of EQ-5D. Value Health. 2016;19:343–52.CrossRef Versteegh M, Vermeulen MM, M A A Evers K, de Wit S, Prenger GA. A Stolk E. Dutch Tariff for the five-level version of EQ-5D. Value Health. 2016;19:343–52.CrossRef
23.
go back to reference van de Poll-Franse L, Horevoorts N, Schoormans D, Beijer S, Ezendam NPM, Husson O, et al. Measuring Clinical, Biological, and behavioral variables to elucidate trajectories of patient (reported) outcomes: the PROFILES Registry. J Natl Cancer Inst. 2022;114:800–7.CrossRefPubMedPubMedCentral van de Poll-Franse L, Horevoorts N, Schoormans D, Beijer S, Ezendam NPM, Husson O, et al. Measuring Clinical, Biological, and behavioral variables to elucidate trajectories of patient (reported) outcomes: the PROFILES Registry. J Natl Cancer Inst. 2022;114:800–7.CrossRefPubMedPubMedCentral
24.
go back to reference Billingy NE, Tromp VNMF, Veldhuijzen E, Belderbos J, Aaronson NK, Feldman E, et al. SYMptom monitoring with patient-reported outcomes using a web application among patients with lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. BMJ Open. 2021;11:e052494.CrossRefPubMedPubMedCentral Billingy NE, Tromp VNMF, Veldhuijzen E, Belderbos J, Aaronson NK, Feldman E, et al. SYMptom monitoring with patient-reported outcomes using a web application among patients with lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial. BMJ Open. 2021;11:e052494.CrossRefPubMedPubMedCentral
26.
go back to reference Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, et al. Composite grading algorithm for the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials. 2021;18:104–14.CrossRefPubMed Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, et al. Composite grading algorithm for the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials. 2021;18:104–14.CrossRefPubMed
27.
go back to reference Rothrock NE, Jensen SE, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, et al. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. Value Health. 2013;16:789–96.CrossRefPubMedPubMedCentral Rothrock NE, Jensen SE, Beaumont JL, Abernethy AP, Jacobsen PB, Syrjala K, et al. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. Value Health. 2013;16:789–96.CrossRefPubMedPubMedCentral
29.
go back to reference Vissers PAJ, Martucci RB, Mols F, Bours MJL, Winkels RM, Kampman E, et al. The impact of body Mass Index and Waist circumference on Health-related quality of Life among Colorectal Cancer Survivors: results from the PROFILES Registry. Nutr Cancer. 2017;69:1177–84.CrossRefPubMed Vissers PAJ, Martucci RB, Mols F, Bours MJL, Winkels RM, Kampman E, et al. The impact of body Mass Index and Waist circumference on Health-related quality of Life among Colorectal Cancer Survivors: results from the PROFILES Registry. Nutr Cancer. 2017;69:1177–84.CrossRefPubMed
30.
go back to reference Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56:1163–9.CrossRefPubMed Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56:1163–9.CrossRefPubMed
31.
go back to reference Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1–32.CrossRefPubMed Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1–32.CrossRefPubMed
32.
go back to reference Ethica Data. https://ethicadata.com. Accessed 5 Aug 2021. Ethica Data. https://​ethicadata.​com.​ Accessed 5 Aug 2021.
33.
go back to reference Greidanus MA, de Boer AGEM, de Rijk AE, Brouwers S, de Reijke TM, Kersten MJ, et al. The successful Return-To-Work questionnaire for Cancer Survivors (I-RTW_CS): development, validity and reproducibility. Patient. 2020;13:567–82.CrossRefPubMedPubMedCentral Greidanus MA, de Boer AGEM, de Rijk AE, Brouwers S, de Reijke TM, Kersten MJ, et al. The successful Return-To-Work questionnaire for Cancer Survivors (I-RTW_CS): development, validity and reproducibility. Patient. 2020;13:567–82.CrossRefPubMedPubMedCentral
34.
go back to reference Ilmarinen J. The work ability index (WAI). Occup Med (Chic Ill). 2006;57:160–0.CrossRef Ilmarinen J. The work ability index (WAI). Occup Med (Chic Ill). 2006;57:160–0.CrossRef
35.
go back to reference Dutch Federation. of Organizations for Cancer patients (Dutch: Nederlandse Federatie van Kankerpatienten organisaties). https://nfk.nl. Accessed 4 Jun 2021. Dutch Federation. of Organizations for Cancer patients (Dutch: Nederlandse Federatie van Kankerpatienten organisaties). https://​nfk.​nl. Accessed 4 Jun 2021.
38.
go back to reference Richters A, Meijer RP, Mehra N, Boormans JL, van der Heijden AG, van der Heijden MS, et al. Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the “trials within cohorts” study ProBCI. BMJ Open. 2021;11:e047256.CrossRefPubMedPubMedCentral Richters A, Meijer RP, Mehra N, Boormans JL, van der Heijden AG, van der Heijden MS, et al. Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the “trials within cohorts” study ProBCI. BMJ Open. 2021;11:e047256.CrossRefPubMedPubMedCentral
40.
go back to reference Burbach JPM, Kurk SA, van den Coebergh RRJ, Dik VK, May AM, Meijer GA, et al. Prospective dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncol (Madr). 2016;55:1273–80.CrossRef Burbach JPM, Kurk SA, van den Coebergh RRJ, Dik VK, May AM, Meijer GA, et al. Prospective dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncol (Madr). 2016;55:1273–80.CrossRef
42.
go back to reference Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7:141–8.CrossRefPubMed Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7:141–8.CrossRefPubMed
Metadata
Title
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs
Authors
Hilin Yildirim
Christiaan V Widdershoven
Maureen JB Aarts
Axel Bex
Haiko J Bloemendal
Deirdre M Bochove-Overgaauw
Paul Hamberg
Karin H Herbschleb
Tom van der Hulle
Brunolf W Lagerveld
Martijn GH van Oijen
Sjoukje F Oosting
Johannes V van Thienen
Astrid AM van der Veldt
Hans M Westgeest
Evelijn E Zeijdner
Katja KH Aben
Corina van den Hurk
Patricia J Zondervan
Adriaan D Bins
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11094-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine